Amycretin is quickly becoming one of the most watched names in obesity medicine, with early trial data showing weight loss figures approaching what is typically seen only after bariatric surgery. Developed by Novo Nordisk, the makers of Ozempic and Wegovy, amycretin is a first-in-class molecule designed to target two hunger hormones at once. It comes in both an injectable and an oral pill form, and it delivered up to 24.3% weight loss in early trials, which is why headlines have called it a potential game-changer. This guide breaks down how amycretin works, what the clinical data shows, how it compares to tirzepatide, retatrutide, and CagriSema, plus expected release timelines, cost expectations, side effects, and safe alternatives available today for patients who cannot wait.
What Is Amycretin? Novo Nordisk’s New Peptide Explained
When people ask what is amycretin, the short answer is that it is a novel investigational drug developed by Novo Nordisk for the treatment of obesity and type 2 diabetes. Also known by the codes NN9487, NNC0487-0111, and the name Zenagamtide, the amycretin peptide is the pharmaceutical industry’s first single molecule that activates both GLP-1 and amylin receptors at the same time. Who makes amycretin? It is manufactured by Danish drugmaker Novo Nordisk (ticker: NVO), and the novo nordisk amycretin program is one of the company’s most closely watched next-generation candidates. In terms of amycretin pronunciation in English, most researchers say it as “am-ee-CREE-tin.” The novo amycretin project sits alongside CagriSema in the company’s post-semaglutide pipeline, and the amycretin Wikipedia entry now reflects its rapid clinical progress.
How Does Amycretin Work: Mechanism of Action, Structure and Molecule
The amycretin mechanism of action is what makes it so unique. Instead of targeting only GLP-1 like Ozempic or GLP-1 plus GIP like Zepbound, amycretin combines GLP-1 and amylin agonism in one molecule. So how does amycretin work in the body? GLP-1 activity reduces appetite, slows gastric emptying, and improves insulin response, while amylin activity further suppresses appetite and helps regulate energy balance. The amycretin structure, or more specifically the amycretin chemical structure, contains two covalently linked peptides that act as analogs of GLP-1 and amylin respectively. The amycretin molecule fits both receptors at once, and the amycretin sequence is engineered for extended half-life to enable weekly injection or daily oral dosing. Learn more about this class in the guide to GLP-1 receptor agonists for weight loss.
Amycretin Pill: The Oral Tablet Formulation
The amycretin pill is one of the most anticipated aspects of this drug. Oral amycretin, sometimes called novo oral amycretin or oral amycretin Novo Nordisk in industry coverage, uses a permeation enhancer called SNAC (the same technology used in Rybelsus) to help the peptide survive the digestive tract. The amycretin tablet is designed for once-daily use on an empty stomach. In early trials, oral amycretin (also referred to as amycretin pills or the weight loss pill amycretin in headlines) produced around 13% weight loss in just 12 weeks, and phase 2 dose-ranging data suggested even higher reductions at top doses. The amycretin weight loss pill format matters because it removes the barrier of self-injection for many patients.
Subcutaneous Amycretin: The Once-Weekly Injection
Subcutaneous amycretin is the injectable version being developed in parallel with the pill. The injectable format uses once-weekly dosing, similar to Wegovy or Zepbound, and it has produced the strongest weight loss numbers so far. In the phase 1b/2a study, subcutaneous amycretin delivered up to 24.3% body weight reduction at the 60mg dose over 36 weeks, with no plateau observed at the end of the treatment period. This is one of the highest weight loss figures ever reported for a non-surgical treatment. The injection route allows for higher peptide bioavailability, which is why the subcutaneous version is expected to launch first in most markets.
Amycretin Clinical Trial Timeline: Phase 1, Phase 2, and Phase 3
The amycretin clinical trial program has moved quickly. The first-in-human amycretin phase 1 study evaluated oral amycretin in patients with obesity and confirmed safety. The next major amycretin trial, a phase 1b/2a subcutaneous study, showed dose-dependent weight loss up to 24.3%. The amycretin phase 2 program in type 2 diabetes (published November 2025) enrolled 448 patients and confirmed both weight and HbA1c benefits. Novo Nordisk has now launched the amycretin phase 3 trial (AMAZE 1, ClinicalTrials.gov ID NCT07339423) as part of the novo nordisk amycretin phase 3 2026 program, and the novo nordisk amycretin phase 3 rollout will cover obesity and type 2 diabetes. Multiple amycretin trials, including the novo nordisk amycretin trial in T2D and the amycretin pill trial in obesity, are running in parallel across US and international sites. The amycretin study data has consistently supported safety and efficacy.
Amycretin Weight Loss Results: What the Data Shows
Amycretin weight loss results have generated significant clinical interest. In the phase 1b/2a study, participants on the 60mg dose lost an average of 24.3% of body weight in 36 weeks compared with just 1.1% for placebo. The amycretin phase 2 weight loss results in type 2 diabetes patients showed 14.5% weight loss with the injection and 10.1% with the oral pill, alongside an HbA1c drop of roughly 1.8 percentage points at the top dose. These amycretin results and amycretin data are the reason novo nordisk’s new drug amycretin shows significant weight loss potential and could rival some bariatric surgery outcomes, though drug-induced weight loss often reverses upon discontinuation. The amycretin phase 2 results give real hope for combined obesity and metabolic care.
Amycretin Side Effects: What Trials Have Shown
Amycretin side effects reported in trials so far are consistent with other GLP-1 based medications. The most common issues are gastrointestinal, including nausea, vomiting, diarrhea, and reduced appetite. Most were mild to moderate and improved as the body adjusted. The amycretin pill side effects appear similar to the injectable version, with a small percentage of participants withdrawing from trials due to adverse events. Serious side effects have been rare in the studies published to date, but long-term safety and rare adverse events will only be confirmed through phase 3. Any patient considering GLP-1 based therapy should discuss risks such as pancreatitis, gallbladder issues, and thyroid concerns with a qualified physician. Class-wide GI issues are also covered in the Ozempic foods to avoid guide.
Amycretin News and Novo Nordisk Pipeline Updates 2026
The latest amycretin news reflects a period of rapid movement. The most important novo nordisk amycretin news in late 2025 was the successful phase 2 trial in type 2 diabetes, which pushed the drug into phase 3 planning. The amycretin novo nordisk news cycle has also focused on how the drug fits into the pipeline as semaglutide patents approach expiry around 2031-2032. The amycretin novo nordisk status 2026 confirms that Novo Nordisk is racing to bring both oral and subcutaneous amycretin to market. Broader novo nordisk pipeline updates 2026 cagrisema amycretin coverage shows that both drugs are being developed as post-semaglutide bets. For investors, the amycretin stock (NVO) reaction has generally been positive following each major data release.
Amycretin vs Tirzepatide, Retatrutide, Zepbound, and Orforglipron
Comparisons to competitors are inevitable. Amycretin vs tirzepatide is one of the most searched matchups, since tirzepatide (the active ingredient in Zepbound and Mounjaro) currently sets the benchmark for GLP-1 class weight loss. Early data suggests amycretin vs zepbound could favor amycretin in peak percentage weight loss, though head-to-head trials are needed. Amycretin vs retatrutide (Eli Lilly’s triple agonist) is another close race, and while retatrutide vs amycretin efficacy looks similar in early studies, amycretin has an oral option. Amycretin vs orforglipron pits amycretin’s dual receptor design against Eli Lilly’s small-molecule oral GLP-1. All of these belong to what analysts call the new weight loss drugs 2026 retatrutide orforglipron amycretin pipeline. For context, review semaglutide vs tirzepatide, Mounjaro vs Zepbound, retatrutide, orforglipron, and Maritide weight loss.
Amycretin vs CagriSema: Novo Nordisk’s Two Next-Gen Bets
Inside Novo Nordisk’s own pipeline, the amycretin cagrisema comparison is the most important internal race. Both are being developed to succeed semaglutide, but they take different paths. CagriSema combines cagrilintide (an amylin analog) with semaglutide as two separate molecules, while amycretin does the same job in a single molecule. The amycretin vs cagrisema data so far suggests amycretin may deliver deeper weight loss, though cagrisema vs amycretin comparisons also weigh safety, tolerability, and dosing convenience. When looking at orforglipron amycretin cagrisema weight loss efficacy across the whole 2026 pipeline, amycretin currently leads in peak percentage weight loss reported. Patients wanting more on this space can read the guide on CagriSema and Survodutide.
Amycretin Cost, Price and Prescription
Because amycretin is not yet FDA approved, an official amycretin cost, amycretin pill cost, or amycretin price has not been set. Based on class pricing for Ozempic, Wegovy, Mounjaro, and Zepbound, industry analysts expect the amycretin pill cost without insurance and amycretin pill cost in USA to land in the $900 to $1,400 per month range at launch, in line with early novo nordisk amycretin pill cost projections. An amycretin prescription will only be available once the FDA approves the drug, and insurance coverage will depend on individual insurer decisions. Anyone considering GLP-1 therapy today can review the Ozempic and Wegovy cost without insurance guide or the semaglutide dosing chart for a real-world reference.
Amycretin Release Date: When Will Amycretin Be Available?
The most common patient question is about the amycretin release date. Based on current phase 3 timelines, when will amycretin be available? A realistic FDA decision window is 2028 to 2029 for the injectable version, with the oral pill possibly following later. Currently, is amycretin available? No. Is amycretin available in USA? Also no. Neither the injectable amycretin available in USA nor the amycretin pill available in USA is on the market yet. Amycretin patent protection is held by Novo Nordisk, so biosimilar or generic options will not be possible until well after launch. Patients frustrated by the wait can explore FDA-cleared options like Foundayo, a compounded semaglutide guide, or alternatives to semaglutide.
Amycretin Buy Options: Where to Buy Amycretin and How to Join a Trial
Many patients search for amycretin buy, amycretin buy online, amycretin for sale, amycretin pill for sale, or amycretin pill where to buy, hoping to access the drug early. Others search amycretin where to buy or how to get amycretin, but the important reality is that there is no legitimate way to buy amycretin today. Any website advertising where to buy amycretin, where can i buy amycretin, or amycretin pill where to buy online is either selling a research compound not intended for human use or is an outright scam. The only legal path is a clinical trial. Patients interested in an amycretin clinical trial sign up or amycretin trial sign up can search ClinicalTrials.gov for NCT07339423 (AMAZE 1) or ask their bariatric provider. Never attempt to buy amycretin, purchase unlabeled amycretin pills from gray-market sources, or self-inject an unapproved product; the safety and legal risks are serious. For legitimate options today, review peptides for weight loss and the best injection for weight loss at home.
Amycretin represents one of the most promising steps forward in obesity medicine, but it remains years away from pharmacy shelves. Patients ready to start their weight loss journey today have several proven, physician-led options at BodEvolve Bariatric. Meet with experienced weight loss doctors in Arlington, TX, consult a full team of weight loss surgeons in Dallas. Long-term surgical candidates can also connect with the best bariatric surgeon in Texas, while patients preferring medication can explore the GLP-1 weight loss program or non-surgical weight loss programs available across Dallas, Fort Worth, Richardson, Arlington, and Texarkana.
